Novartis India Share Price

Novartis India

CMP as on 27-May-22 15:29

₹ 592.00
18.15 3.16%

Open

₹ 578.00

Turnover (lac)

₹ 31

Prev. Close

₹ 573.85

Day's Vol (shares)

₹ 5,201

Day's Range (₹)

₹ 571.45
₹ 592.50

CMP as on27-May-22 15:28

₹ 592.90
14.5 2.51%

Open

₹ 579.75

Turnover (lac)

₹ 7

Prev. Close

₹ 578.40

Day's Vol (shares)

₹ 479

Day's Range

₹ 574.65
₹ 592.90

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 31-Mar-2022 - -
NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2022 inter alia to consider and approve the Audited financial results of the Company for the fourth quarter and financial year ending on March 31 2022 (said results) and recommendation of final dividend on Equity Share if any for the said year. The Board has recommended final dividend of Rs. 10 per equity share (of the face value of Rs. 5 each) for the financial year ended March 31, 2022, subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting (AGM). Accordingly, the said final dividend, if approved by the shareholders, will be paid on or after August 2, 2022. Outcome of the Meeting of the Board of Directors of Novartis India Limited (the Company) held on May 19, 2022 The Board has recommended the appointment of M/s. B S R & Co. LLP, Chartered Accountants (ICAI FRN: 101248W/W-100022) as Statutory Auditors of the Company for a term of 5 (five) years to hold office from the conclusion of 74th AGM till the conclusion of 79th AGM of the Company subject to the approval of the shareholders at the ensuing AGM. Brief Profile of M/s. B S R & Co. LLP is enclosed herewith. (As Per BSE Announcement Dated on 19.05.2022)
Board Meeting - 27-Apr-2022 - -
Outcome of the Meeting of the Board of Directors of Novartis India Limited held on Wednesday, April 27, 2022 for : 1. Appointment of Chief Financial Officer 2. Appointment of Company Secretary and Compliance Officer
Board Meeting - 11-Feb-2022 - -
Dear Sirs, Please find enclosed herewith the following: 1. Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 2. Media Report Kindly take the same on record.
Board Meeting - 31-Dec-2021 - -
NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2022 inter alia to consider and approve the Unaudited financial results of the Company for the third quarter ending on December 31 2021 . Kindly take the same on record. Dear Sir/ Madam, Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Thursday, February 10, 2022 (said meeting), inter alia considered and approved the Unaudited Financial Results of the Company for the quarter and nine-months ended on December 31, 2021. In terms of the applicable provisions of SEBI Listing Regulations, please find enclosed herewith: a. the Unaudited Financial Results; and b. Limited Review Report dated February 10, 2022, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and taken on record by the Board of Directors of the Company. The said Meeting commenced at 11:15 a.m. and concluded at 2:35 p.m. The above is for your information and the same is also available on the Companys website i.e. www.novartis.in (As Per BSE Announcement Dated on 10/02/2022)
Board Meeting - 30-Sep-2021 - -
Quarterly Results NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2021 ,inter alia, to consider and approve the Unaudited financial results of the Company for the second quarter ending on September 30, 2021. Dear Sir/ Madam, Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Thursday, November 11, 2021 (said meeting), inter alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2021. Further, pursuant to Regulation 30 of SEBI LODR Regulations, we would like to inform you that Mr. Trivikram Guda has tendered his resignation from the position of the Company Secretary and Compliance Officer of the Company, to pursue opportunities outside of Novartis. The resignation is accepted and he will be relieved from his responsibilities at the end of business hours on November 30, 2021. The Company is in the process of identifying a suitable successor and the same will be communicated to the stock exchange, once the position is filled up. The said meeting commenced at 11:30 a.m. and concluded at 3:00 p.m. (As Per BSE Announcement Dated 11.11.2021)
Board Meeting - 30-Jun-2021 - -
NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2021 ,inter alia, to consider and approve the Unaudited financial results of the Company for the first quarter ending on June 30, 2021 (said results). Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Wednesday, August 11, 2021 (said meeting), inter alia considered and approved the Unaudited Financial Results of the Company for the first quarter ended on June 30, 2021. In terms of the applicable provisions of SEBI Listing Regulations, please find enclosed herewith: the Unaudited Financial Results; and Limited Review Report dated August 11, 2021, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and taken on record by the Board of Directors of the Company, as Annexure 1. The said Meeting commenced at 11:30 a.m. and concluded at 2:20 p.m. The above is for your information and the same is also available on the Companys website i.e. www.novartis.in (As Per BSE Announcement Dated on 11.08.2021)
Board Meeting - 31-Mar-2021 - -
NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2021 ,inter alia, to consider and approve the Audited financial results of the Company for the fourth quarter and financial year ending on March 31, 2021 (said results) and recommendation of final dividend on Equity Share, if any, for the said year. Final Dividend (Revised) & Audited Results (As per BSE Bulletin Dated on 11/05/2021) Dear Sir/ Madam, This is further to our letter dated March 31, 2021 with respect to the intimation of the meeting of the Board of Directors of the Company scheduled to be held on Thursday, May 20, 2021. In that regard, this is to inform that the said Board Meeting of the Company has been re-scheduled and will now be held on Thursday, June 17, 2021, to inter alia consider the Audited financial results of the Company for the fourth quarter and financial year ending on March 31, 2021 (said results) and recommendation of final dividend on Equity Share, if any, for the said year. In this connection, further note that pursuant to the Companys Code of Conduct to regulate, monitor and report share trading by Insiders [the Code], the trading window for dealing in securities of the Company which was earlier closed from Thursday, April 1, 2021 to Saturday, May 22, 2021 (both days inclusive) shall continue to remain closed till Saturday, June 19, 2021. This is for your information. (AS Per BSE Announcement Dated on 11.05.2021) Intimation of Newspaper advertisement by Novartis India Limited regarding re-scheduling of meeting of the Board of Directors of the Company for the fourth quarter and year ended March 31, 2021 in Financial Express and Navshakti, on May 12, 2021. (As Per BSE Announcement dated on 12.05.2021) Novartis India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 17, 2021, inter alia, have approved the following: - Recommendation of final dividend of Rs. 10/- per Equity share of Rs. 5/- each for the year ended March 31, 2021, subject to approval of the shareholders of the Company. Enclosed herewith is the detailed outcome of the Meeting. (As Per BSE Announcement Dated on 17.06.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity